Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi AppTec Pays $46.4 Million to Acquire 15% Stake in its STA Subsidiary

publication date: Apr 22, 2019

WuXi AppTec, China's largest CRO, will pay $46.4 million to acquire a 15% outstanding stake in its STA Pharma, WuXi's small molecule manufacturing division. In 2014, WuXi AppTec sold the shares to STA management and investors, and then listed STA on China's NEEQ, an over-the-counter exchange. It withdrew the listing last month. In 2017, WuXi AppTec merged STA into its small molecule R&D division so that clients would have a full complement of CRO/CDMO services available from a single company. More details....

Stock Symbols: (SHA: 603259; HK: 2359)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here